R&D channel feed – Endpoints News

R&D channel feed

Eli Lilly shutters the last PhIII sola study, certain of failure

9 years ago

Tenax endures (another) clinical catastrophe as its PhIII flops, shares blitzed

9 years ago

After a PhII catastrophe wiped out a billion dollars in market cap, Seres is looking for a do-over

9 years ago

Microcap biotech Ocera craters on a PhIIb failure for hepatic encephalopathy

9 years ago

FibroGen, AstraZeneca ready China application as anemia drug scores in two pivotal studies

9 years ago

Novo Nordisk shrugs off Brexit, unveils $144M plan for a diabetes research center at Oxford

9 years ago

Regulus ordered to remain in limbo as FDA refuses to lift hold, demanding more data on lead drug

9 years ago

Novan’s shares in meltdown following "discordant" PhIII studies of a new acne drug

9 years ago

Ouch: Eli Lilly is walking away from Adocia deal and its ultra-fast insulin — for the second time

9 years ago

Highland who? Biotech gets a $200M war chest to crack the US ADHD market

9 years ago

Investigators detail some of the hopes – and fears – behind Cellectis' off-the-shelf CAR-T

9 years ago

Eisai plots new drug applications in US, Europe and China after Lenvima scores in head-to-head liver cancer study

9 years ago

Fighting a generic onslaught, Novartis adds CAR-T to its growing list of late-stage blockbusters

9 years ago

Women are gaining more board seats in biotech, but real change is happening at a snail's pace

9 years ago

An upstart immunotherapy biotech emerges from stealth mode with big love for Kendall Square

9 years ago

Struggling Marinus gets a bump out of a positive PhII snapshot

9 years ago

Deep in talks with J&J, Actelion’s flagship drug cruises past a pivotal trial failure

9 years ago

Ovid adds $26M to its coffers as Takeda deal closes, building a war chest for pipeline construction work

9 years ago

Bristol-Myers staggered by a stunning checkpoint setback, hands Merck a free pass on frontline lung cancer combo

9 years ago

Shire finally finishes a 10-year trek back to the FDA with an old ADHD drug

9 years ago

Dermira sweeps PhIII psoriasis studies for Cimzia as rivals threaten another entry

9 years ago

Novartis chief Jimenez touts two top PhIII drug prospects

9 years ago

Neurocrine execs shrug off a PhII setback for Tourette syndrome

9 years ago

Lagging further behind, AstraZeneca adds fresh details to its checkpoint comeback strategy

9 years ago

First page Previous page 307 308 309310311 312 313 Next page Last page